Search

Displaying results 4261 - 4270 of 10000 in total
  1. Drug

    Viral Macrophage-Inflammatory Protein

    go.drugbank.com/drugs/DB15748
    Experimental

    Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. … The structure of vMIP consists of 71 residues and is a monomer under most conditions.

    Synonyms: vMIP-II, Viral Macrophage Inflammatory Protein-II
  2. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load. … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.

  3. Drug

    Paclitaxel docosahexaenoic acid

    go.drugbank.com/drugs/DB05297
    Investigational

    A combination of [docosahexaenoic Acid] (a natural fatty acid) and [paclitaxel] (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.

  4. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  5. Drug

    Denatonium

    go.drugbank.com/drugs/DB18588
    Investigational

    Synonyms: Benzenemethanaminium, n-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-n,n-diethylCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797] … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.

  7. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility

  8. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. … It is developed by MedImmune for the treatment of Allergic Rhinitis.

  9. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  10. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase